CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: A logical progression

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 1, 2007, Pages

  Tacket, Carol O ^a   Levine, Myron M ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CVD 908; CVD 908 HTRA; CVD 909; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; POLIOMYELITIS VACCINE; RUBELLA VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; AROC GENE; AROD GENE; BACTEREMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; GENE; GENE DELETION; GENE MUTATION; HTRA GENE; HUMAN; IMMUNOGENICITY; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; REVIEW; SALMONELLA ENTERICA; SALMONELLA TYPHI; SINGLE DRUG DOSE; TYPHOID FEVER; VACCINATION; VACCINE PRODUCTION; VIREMIA;

ADMINISTRATION, ORAL; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ORGANISMS, GENETICALLY MODIFIED; SALMONELLA TYPHI; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

EID: 34447122536     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/518135     Document Type: Review

References (26)

1. Germanier R, Furer E. Isolation and characterization of gal E mutant Ty21a of Salmonella typhi: a candidate strain for a live oral typhoid vaccine. J Infect Dis 1975; 141:553-8.
2. Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 1996; 173:1408-14.
3. Tacket CO, Hone DM, Curtiss RI, et al. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect Immun 1992; 60:536-41.
4. Kirkpatrick BD, Tenney KM, Larsson CJ, et al. The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine preparations. J Infect Dis 2005; 192:360-6.
5. Hoiseth SK, Stocker BAD. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981; 291:238-9.
6. Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM. Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine 1991; 9:810-6.
7. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain. Vaccine 1992; 10:443-6.
8. Tacket CO, Sztein MB, Losonsky GA, et al. Safety and immune response in humans of live oral Salmonella typhi vaccine strains deleted in htrA and aroC aroD. Infect Immun 1997; 65:452-6.
9. Levine MM, Galen J, Barry E, et al. Attenuated Salmonella as live oral vaccines against typhoid fever and as live vectors. J Biotechnol 1996; 44:193-6.
10. Balfour HH, Groth KE, Edelman CK, Amren DP, Best JM, Banatvala JE. Rubella viremia and antibody responses after rubella vaccination and reimmunization. Lancet 1981; 1:1078-80.
11. Horstmann DM, Opton EM, Klempferer R, Llado B, Vignec AJ. Viremia in infants vaccinated with oral poliovirus vaccine (Sabin). Am J Hyg 1964; 79:47-63.
12. Melnick JL, Proctor RO, Ocampo AR, Diwan AR, Ben-Porath E. Free and bound virus in serum after administration of oral poliovirus vaccine. Am J Epidemiol 1966; 84:329-42.
13. Johnson K, Charles I, Dougan G, et al. The role of a stress-response protein in Salmonella typhimurium virulence. Mol Microbiol 1991; 5:401-7.
14. + T cell responses in volunteers immunized with Salmonella enterica serovar typhi strain CVD 908-htrA. J Immunol 2003; 170:2734-41.
15. Tacket CO, Sztein MB, Wasserman SS, et al. Phase 2 clinical trial of attenuated Salmonella typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68:1196-201.
16. Black R, Levine MM, Young C, et al. Immunogenicity of Ty21a attenuated Salmonella typhi given with sodium bicarbonate or in enteric coated capsules. Dev Biol Stand 1983; 53:9-14.
17. Klugman KP, Gilbertson IT, Koornhof HJ, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet 1987; 2:1165-9.
18. Acharya IL, Lowe CU, Thapa R, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report. N Engl J Med 1987; 317:1101-4.
19. Robbins JD, Robbins JB. Reexamination of the protective role of the capsular polysaccharide Vi antigen of Salmonella typhi. J Infect Dis 1984; 150:436-49.
20. Arricau N, Hermant D, Waxin H, Ecobichon C, Duffey PS, Popoff MY, The RcsB-RcsC regulatory system of Salmonella typhi differentially modulates the expression of invasion proteins, flagellin and Vi antigen in response to osmolarity. Mol Microbiol 1998; 29:835-50.
21. Virlogeux I, Waxin H, Ecobichon C, Lee JO, Poposs MY. Characterization of the rcsA and rcsB genes from Salmonella typhi: rcsB through tviA is involved in regulation of Vi antigen synthesis. J Bacteriol 1996; 178:1691-8.
22. Pickard D, Li J, Roberts M, Maskell D, Hone D, Levine M. Characterization of defined ompR mutants of Salmonella typhi: ompR is involved in the regulation of Vi polysaccharide expression. Infect Immun 1994; 62:3984-93.
23. Wang JY Noriega FR, Galen JE, Barry E, Levine MM. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar Typhi oral vaccine strain CVD 909. Infect Immun 2000; 68:4647-52.
24. Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis 2004; 190:565-70.
25. World Health Organization. Typhoid vaccines. WHO position paper. Weekly Epidemiological Record 2000; 75:257-64.
26. Canh do G, Lin FY, Thiem VD, et al. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 2004; 72:6586-8.